CLINICAL TRIALS PROFILE FOR GALLIUM GA 68 EDOTREOTIDE
✉ Email this page to a colleague
All Clinical Trials for GALLIUM GA 68 EDOTREOTIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03001349 ↗ | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | Terminated | National Cancer Institute (NCI) | Early Phase 1 | 2017-05-16 | This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors. |
NCT03001349 ↗ | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | Terminated | M.D. Anderson Cancer Center | Early Phase 1 | 2017-05-16 | This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GALLIUM GA 68 EDOTREOTIDE
Condition Name
Condition Name for GALLIUM GA 68 EDOTREOTIDE | |
Intervention | Trials |
Metastatic Well Differentiated Neuroendocrine Neoplasm | 1 |
Multiple Endocrine Neoplasia Type 1 | 1 |
Neuroendocrine Neoplasm | 1 |
Somatostatin Positive Neoplastic Cells Present | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for GALLIUM GA 68 EDOTREOTIDE
Trials by Country
Clinical Trial Progress for GALLIUM GA 68 EDOTREOTIDE
Clinical Trial Phase
Clinical Trial Sponsors for GALLIUM GA 68 EDOTREOTIDE
Sponsor Name